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Background: Inhaled nitric oxide (iNO) is a potent selective pulmonary vasodilator, which is used in
critically ill patients to improve oxygenation. It avoids systemic hypotension and ventilator-induced lung
injury in patients using ventilators. This study explored the medical resource utilization and outcome,
and predicted risk factors for mortality in patients using ventilators with iNO.
Methods: The database was from the National Health Insurance hospital claims data in Taiwan from 2004
to 2009. The patients using ventilators with iNO were collected and stratiﬁed by age to 20e44 years, 45
e64 years, 65e74 years, and  75 years.
Results: Seven hundred and thirty ventilator patients with iNO were enrolled (63.15% male, mean age 60
years). Mechanical ventilation (MV) weaning rate was 18.25%, intensive care unit (ICU) readmission rate
was 5.75%, and ICU mortality rate was 74.52%. ICU mortality rate was lower, case-mix index, MV weaning
rate, and hospital costs were higher for patients aged 20e44 years and 45e64 years than in those aged
65e74 years and  75 years (p < 0.05). Sex, case-mix index, Charlson comorbidity index, whether MV
weaning (p < 0.001), different age group, and implementation of tracheostomy (p < 0.05) were all sig-
niﬁcant risk factors in predicting mortality of patients using ventilators with iNO.
Conclusion: This study showed that the outcome differed with age in patients using ventilators with iNO.
Copyright © 2015, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Conventional vasodilators may easily cause systemic vasodila-
tion,which leads tohypotension;whereas inhaled nitric oxide (iNO)
is a pulmonary vasodilator that selectively enters well-ventilated
alveoli. There is a large afﬁnity between NO and hemoglobin, 1500
times more than that between CO and hemoglobin. The half-life of
NO is short, so it loses its activity before entering the systemic cir-
culation. As a result, NO does not lead to systemic hypotension1e3,
but improves the V/Q (ventilation/perfusion) mismatch of patients
using ventilators, reduces intrapulmonary shunts, increases arterialicts of interest.
ent of Internal Medicine, Chi-
ang District, Tainan 71044,
@gmail.com (K.-C. Cheng).
tric Emergency & Critical Care Meoxygen content, decreases the oxygen concentration of the venti-
lator (FiO2), and lowers pulmonary artery hypertension4e6. Del-
linger et al found that the survival rate and the weaning rate of
5 ppm iNOuserswere the highest7.Whennewbornswith persistent
pulmonary hypertension use iNO, the condition of oxygenationmay
be improved, and the treatment demand of extracorporeal mem-
brane oxygenation may be reduced, which also decreases the ex-
penses of hospitalization8,9. However, some studies found that iNO
was not able to improve the condition of oxygenation, ventilator
weaning rate, and prognosis in patients10,11; or, the improvement
was observed only temporarily, and the mortality rate, length of
mechanical ventilation (MV) utilization, and the number of days in
the intensive care unit (ICU) were not improved12e14.
This study explored the medical resource utilization and
outcome of patient in different age groups using iNO ventilators,
and predicted risk factors for mortality. Through this study, the
conditions of patients using iNO ventilators will be understood
further as references for future clinical applications.dicine. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Baseline characteristics of ventilator patients with inhaled nitric
oxide.
Variable n ¼ 730
Age 60 ± 19
Sex
Male 461 (63.15)
Female 269 (36.85)
CMI 4.63 ± 4.98
CCI
0 211 (28.90)
1 213 (29.18)
2 187 (25.62)
 3 119 (16.30)
MV weaning ratea 129 (18.25)
Readmission ICU rate 42 (5.75)
Tracheostomy rate 72 (9.86)
Antibiotic usage rate 713 (97.67)
ICU mortality 544 (74.52)
Hospital level
Medical center 666 (91.23)
Regional hospital 64 (8.77)
Data are presented as mean ± standard deviation or n (%).
a n ¼ 707.
CCI ¼ Charlson Comorbidity Index; CMI ¼ case-mix index;
MV ¼ mechanical ventilation.
Inhaled NO in Mechanical Ventilation 472. Materials and methods
2.1. Study design and patient selection
The data were provided by the National Health Insurance (NHI)
Bureau from March 1, 2004 to February 28, 2009; the targets were
adult patients from around Taiwan who were in the ICU using MV
with iNO (NHI registration code 57025b). Variables were statisti-
cally analyzed, including patient age, sex, case-mix index (CMI),
Charlson comorbidity index (CCI), mortality rate in ICU, MV
weaning rate, ICU readmission rate, tracheostomy rate, hospitali-
zation cost, antibiotics cost, number of days using iNO, number of
days in ICU, number of days hospitalized, and number of days using
a ventilator. The patient medical resource utilization and outcomes
were analyzed. Risk factors for mortality rate in patients using MV
with iNO were analyzed according to sex, age group, CMI, CCI, MV
weaning rate, and tracheostomy rate.
2.2. Measurements and variables
This study categorized patients into four age groups of 20e44
years, 45e64 years, 65e74 years and  75 years. Hospitals were
categorized into three levels according to their accreditation,
including medical center, regional hospital, and district hospital.
Most iNO patients were found in medical centers and regional
hospitals, therefore, this study excluded data from district hospi-
tals. The regional NHI branches included Taipei, Northern, Central,
Southern, Kao-Ping and Eastern Branches; only the Eastern Branch
had been excluded, because no patients were using iNO. For a
better annual presentation, data collected between March 1, 2004
and February 28, 2005 were presented as 2004; data collected
between March 1, 2005 and February 28, 2006 was presented as
2005, and so on for the remaining data.
Amongst independent variables, medical resource utilization
and disease severity were assessed using CMI and CCI values. When
CMI increased, it meant that the patients in the hospital were more
complicated and used more resources. The CCI values were divided
into four groups, 0, 1, 2, and  3. The CCI value controls the co-
morbidity of patients before treatment or surgery, which avoids
biased efﬁcacy assessment. A developed comorbidity and severity
calibration tool may follow up the prognosis of the patients as a
good indicator. Therewere ﬁve scores, including 0 (no event),1, 2, 3,
and 6; the higher the score, the more severe the disease15. MV
weaning is deﬁned when a patient using iNO leaves the ICU
without carrying a mechanical ventilator. ICU readmission is
deﬁned when a hospitalized patient leaves the ICU and returns
after > 24 hours. The hospitalization expenses were the total re-
ported to the NHI. The dependent variable was patient mortality
rate. Mortality was deﬁned when the patient's status in the NHI
database changed to Code 4 and Code A, and was discharged from
the hospital ICU within 24 hours due to their terminal condition16.
2.3. Statistical analyses
Access 2007, statistics analysis system (SAS), and SPSS for
Windows, version 17.0 (Chicago, IL, USA) were used in this study for
data conversion and analysis. Descriptive analysis, c2 test, and one-
way analysis of variance were used to investigate the medical
resource utilization and outcomes of the patients using iNO. When
themortality risk factors of patients using iNOwere investigated, in
order to keep the cluster effect of the hospital on the prognosis of
the patients, generalized estimating equations model and logit link
function were used. Under the hypothesis of the exchangeable
working correlation matrix, the data were analyzed to calculate the
odds ratio and 95% conﬁdence interval17 of each risk factor.3. Results
This study included 730 patients using MV with iNO; the
average age was 60 years and there were 461men (63.15%) and 269
women (36.85%). The CMI was 4.63. The CCI distribution was 28.9%
for 0, 29.18% for 1, 25.62% for 2 and 16.3% for  3. The tracheostomy
rate was 9.86%; the antibiotics usage rate was 97.67%; and the ICU
mortality rate was 74.52% (Table 1). However, when the MV
weaning rate was calculated, some NHI reporting materials were
missing between 2004 and 2009; after excluding some data, the
total number of patients using iNO MV was 707 and the survival
rate was 18.25% (129 patients).
Table 1 also shows the distribution of patients using MV with
iNO, which includes 666 patients (91.23%) from medical centers
and 64 patients (8.77%) from regional hospitals. On the aspect of
NHI branch, the highest number of iNO users was found in Taipei
Branch, and the lowest number of iNO users was found in Kao-Ping
Branch; the numbers were 498 (68.22%) and 21 (2.88%), respec-
tively (Fig. 1). Patients using MV with iNO were mostly found in
medical centers, but big differences in the distribution of iNO users
in various branches were found; the number of patients in the
medical centers was not proportionally related to the distribution
of the branches. It is predicted that the presence of facilities and the
choice of physicians are related to the number of iNO users in each
hospital.
Among different age groups of the patient using MV with iNO,
the analysis (Table 2) of the medical resource utilization and out-
comes found that, CMI, MV weaning rate and hospitalization
expense of the 20e44 years age group were higher than those of
the 65e74 years and  75 years groups; the antibiotics cost of
20e44 years age group was also higher than that of the  75 years
age group. However, the ICU mortality rate of the 20e44 years age
group was lower than that of the 65e74 years and  75 years
groups; the MV of the 20e44 years age group was also lower than
that of the  75 years age group. The CMI values for the three
groups mentioned were 5.70, 3.14 and 3.22 (p < 0.001), respec-
tively; theMVweaning rates were 40 (25.48%),18 (12.68%, p < 0.05)
and 16 (8.29%, p < 0.001), respectively; the hospitalization costs
were US$25,113, US$17,596 and US$18,507 (p < 0.05), respectively;
the antibiotics costs were US$2,415 and US$1,714 (p < 0.05),
Fig. 1. Distribution of ventilator patients with iNO in different districts of the National Health Bureau in Taiwan.
Y.-C. Chung et al.48respectively; the ICUmortality rates were 114 (69.51%), 117 (80.69%,
p < 0.05), and 166 (83.00%, p < 0.001), respectively; the number of
days using MV was 12.41 days and 18.22 days (p < 0.05),
respectively.
The CMI and hospitalization costs of the 45e64 years age group
were higher than those of the 65e74 years and  75 years groups;
the MV weaning rate of the 45e64 years age group was also higher
than that of the  75 years age group. However, the ICU mortality
rate of the 45e64 years age group was lower than that of the 65e74
years and  75 years groups; the 0 score rate of CCI in the 45e64
years age group was lower than that in the 20e44 years and  75
years groups. In addition, the ICU readmission rate of the 45e64
years age group was lower than that of the  75 years group. The
CMI values were 6.27, 3.14, and 3.22 (p < 0.001), respectively; the
hospitalization costs were US$25,336, US$17,596, and US$18,507
(p < 0.05), respectively; the MV weaning rates were 25.58% (55),
and 8.29% (16, p < 0.001), respectively; the ICUmortality rates were
66.52% (147), 80.69% (117, p < 0.05), and 83% (166, p < 0.001),
respectively; the 0 scoring rates of CCI were 19.91% (44), 34.76% (57,
p < 0.05), and 36% (72, p < 0.05), respectively; the ICU readmission
rates were 4.07% (9) and 9% (18, p < 0.05), respectively. Nosigniﬁcant difference was found in the remaining variables among
the four age groups.
Fig. 2 shows ratios of the mortality rate, the MV weaning rate,
the number of days using MV, and the number of days in ICU be-
tween 2005 and 2008 among patients using MV with iNO. There
were too few samples of patients using MV with iNO and the
weaning rate in 2004, thus, they were excluded from the ﬁnal data.
No signiﬁcant difference was found between 2005 and 2008 for MV
weaning rate, the number of days using MV, and the number of
days in ICU between 2005 and 2008.
Under the hypothesis of generalized estimating equations and
exchangeable working correlation matrix, Table 3 shows the logic
regression of mortality risk factors in patients using MV with iNO
before and after calibration. Of those, before calibration, the hos-
pitalization cost was a signiﬁcant risk factor, but it was not signif-
icant after calibration; whereas, sex, age group, CMI, CCI, MV
weaning, and tracheostomy implementation were signiﬁcant risk
factors for patient mortality, both before and after calibration.
Mortality risk in female patients was 1.56 times (p < 0.001) higher
than that in male patients. Mortality in the  75 years age group
was 1.80 times (p < 0.05) higher than that in the 20e44 years age
Table 2
Outcome of ventilator patients with iNO stratiﬁed by age.
Age 20e44a 45e64b 65e74 75
Variable (n ¼ 164) (n ¼ 221) (n ¼ 145) (n ¼ 200)
CMI 5.70 ± 5.53 6.27 ± 6.65 3.14 ± 2.94** 3.22 ± 2.36**
CCI
0 57 (34.76) 44 (19.91)a 38 (26.21) 72 (36.00)b
1 43 (26.22) 68 (30.77) 40 (27.58) 62 (31.00)
2 41 (25.00) 66 (29.86) 38 (26.21) 42 (21.00)
 3 23 (14.02) 43 (19.46) 29 (20.00) 24 (12.00)
ICU mortality 114 (69.51) 147 (66.52) 117 (80.69)* 166 (83.00)**
MV weaning rate 40 (25.48) 55 (25.58) 18 (12.68)a 16 (8.29)**
Readmission ICU rate 7 (4.27) 9 (4.07) 8 (5.52) 18 (9.00)b
Tracheostomy rate 13 (7.93) 20 (9.05) 11 (7.59) 28 (14.00)
Hospital expense (USD) 25,113 ± 18,043 25,336 ± 26,699 17,596 ± l7,706* 18,507 ± 19,451*
Antibiotics expense (USD) 2,415 ± 3,085 1,995 ± 2,374 1,719 ± 2,411 l,714 ± l,621a
NO duration (Day) 5.58 ± 4.83 5.61 ± 5.83 4.52 ± 3.49 5.04 ± 4.12
5 (2~7) 4 (2~7) 4 (2~6) 4 (2~7)
ICU duration (Day) 18.29 ± 16.71 21.06 ± 29.81 17.85 ± 23.15 22.48 ± 22.48
14.50 (7~23) 13 (5~24) 12 (5~25) 17 (9~21)
Hospital duration (Day) 28.70 ± 21.09 33.72 ± 40.92 28.03 ± 31.90 30.57 ± 34.93
25 (12.50~39.50) 22 (12~41) 21 (8~37) 23 (12.5~37)
MV duration (Day) 12.41 ± 14.86 15.60 ± 23.52 13.41 ± 18.63 18.22 ± 23.90a
8 (3.5~16) 8 (4~16) 7 (2~19) 13 (5~23)
One-way ANOVA test; post hoc tests (Bonferroni).
Data are presented as mean ± SD and median (IQR) or n (%).
*p < 0.05; **p < 0.001.
a Compared to 20e44.
b Compared to 45e64.
CCI ¼ Charlson Comorbidity Index; CMI ¼ case-mix index; IQR ¼ interquartile range; MV ¼ mechanical ventilation.
Inhaled NO in Mechanical Ventilation 49group. The risk of patient mortality decreased by 7% (p < 0.001)
when the CMI increased by 1. The risk of mortality for patients with
CCI 3was 3.33 times (p< 0.001) higher than that with CCI value 0.
The risk of mortality for patients not weaning from MV was 2.98
times (p < 0.001) higher than that in patients who were weaning
from MV. The risk of mortality for patients without tracheostomy
was 3.02 times (p < 0.05) higher than that in patients with
tracheostomy.66.46%71.43%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2006
Fig. 2. Data of patients using ventilators w4. Discussion
Overseas studies showed that patients using MVwith iNO could
not improve the weaning rate and mortality rate; it was also not
related to the number of days using MV and staying in the ICU18e20.
When the present study investigated resource utilization and
outcomes of patients using MV with iNO, it was found that the
overall MV weaning rate was low and the mortality rate was high,77.95%78.26%
2007 2008
Year
Day
ith inhaled nitric oxide in 2005e2008.
Table 3
Predicting factors for mortality of ventilator patients with inhaled nitric oxidea
Variable Crude OR
(95% CI)
p Adjusted OR
(95% CI)
pb
Female vs. male 1.36 (1.10e1.68) < 0.05 1.56 (1.20e2.04) < 0.001
Age level (y)
20e44 Ref. Ref.
45e64 0.99 (0.65e1.49) 0.95 1.02 (0.66e1.58) 0.93
65e74 1.80 (0.97e3.34) 0.06 1.63 (0.94e2.82) 0.08
 75 1.65 (1.05e2.59) < 0.05 1.80 (1.14e2.83) < 0.05
CMI 0.93 (0.90e0.95) < 0.001 0.93 (0.90e0.96) < 0.001
CCI
0 Ref. Ref.
1 0.92 (0.71e1.19) 0.53 1.11 (0.84e1.47) 0.45
2 0.96 (0.71e1.31) 0.80 1.20 (0.79e1.82) 0.39
 3 3.29 (2.05e5.29) < 0.001 3.33 (1.88e5.88) < 0.001
MV weaning
(no vs. yes)
2.39 (1.42e4.00) < 0.001 2.98 (1.53e5.83) < 0.001
Tracheostomy
(no vs. yes)
2.10 (1.31e3.37) < 0.05 3.02 (1.47e6.21) < 0.05
Hospital cost
(USD)
1.0 (0.99e1.0) < 0.05 1.0 (1.0e1.0) 0.98
a Multiple logistic regression using generalized estimating equations models.
b Adjusted for sex, age, CMI, CCI, MV weaning, tracheostomy, hospital cost.
CCI ¼ Charlson Comorbidity Index; CI ¼ conﬁdence interval; CMI ¼ case-mix index;
MV ¼ mechanical ventilation; OR ¼ odds ratio.
Y.-C. Chung et al.50which were 18.25% and 74.52%, respectively (Table 1). Further, the
trend of iNO using patient between 2005 and 2008 was observed
(Fig. 2). The MV weaning rates were 24.04%, 20.92%, 17.07% and
15.10%, respectively, categorized by year; the mortality rates were
71.43%, 66.46%, 78.26% and 77.95%, respectively, categorized by
year; the numbers of days using MV were 16.72, 16.40, 12.08 and
16.24, respectively, categorized by year; the numbers of days
staying in the ICU were 20.93, 20.55, 16.68 and 16.24, respectively,
categorized by year. No signiﬁcant difference was found in the MV
weaning rate, mortality rate, number of days using MV, and num-
ber of days staying in the ICU among the 4 years studied. Unfor-
tunately, this study did not compare patients using MV with and
without iNO. Although no signiﬁcant improvement was found in
the data from those 4 years, further studies are required to clarify
whether iNO treatment improves MV weaning rate and mortality
rate, and whether iNO affects the number of days using MV and
staying in the ICU.
The present study showed that CMI, MV weaning rate, hospi-
talization cost and antibiotics costs of the 20e44 years and 45e64
years age groups were higher than those of the 65e74 years and 
75 years age groups; however, the ICU readmission rate and the
number of days using MV in the two younger age groups were
lower than in the two older age groups. Even the 0 scoring rate of
CCI for the 75 years age groupwas higher than that for the 45e64
years age group, and the ICU mortality rates for the 65e74 years
and  75 years age groups were still higher than for the two
younger groups. It is suggested that the condition of the older
groups was not that severe, but the mortality rate remained higher.
In addition, other studies in Taiwan have been performed on the
tracheostomy rate and the mortality rate of middle-aged and old-
aged patients using MV. They showed that the tracheostomy rate
decreased annually in the  75 years age group, but the rate and
mortality were still higher than in the other younger groups16. This
study also found that patients using iNO aged  75 years had a
similar tracheostomy rate compared to other age groups, but their
mortality rate was 1.80 times (p < 0.001, Table 3) higher than that of
the 20e44 years age group.
The younger groups had a higher rate of using the medical
resource utilization and better prognosis compared to the older
groups. It reminds us that wemay ﬁnd a balance point for the older
groups to maximize the medical resource utilization and obey theethics. In 2000, implementation of the Hospice Palliative Care Act
was announced for 2001; meanwhile, the Department of Health
also actively promoted a “do not resuscitate” policy, which has the
hope that older and end-stage patients may be transferred to a
hospice ward for more supportive treatment. The policy and
regulation described above may make a difference in the rate of
medical resource utilization, care quality, and prognosis. It is
believed that these policies and regulations may resolve the
problems described above; however, whether they can be suc-
cessfully implemented remains to be assessed.
Hospice palliative care is a consistent caring trend in many
countries for incurable or end-stage patients, whose pain and
symptoms may be controlled and relieved. Their mental, social,
and spiritual aspects are taken care of, and their willingness to
undergo treatment is respected, to minimize any unnecessary
suffering and pain, and to optimize the quality of life with the new
caring model16.
There were some limitations in this study. First, a retrospective
study using the NHI database related to the hospital registration
materials may not be consistent, due to the different habits and
reporting systems among the hospitals; it is possible that some
data were missed. Clinically, the severity indicators are often used,
such as the acute physiology and chronic health evaluation II
(APACHE II) score, and biochemical tests, including arterial oxygen
content and concentration; however, some data might not be ﬁled
in the NHI database. In future, if a prospective study can be per-
formed, detailed records, clinical data, and discussions about the
appropriate timing of iNO utilization may improve the oxygenation
condition in patients and optimize the care quality and prognosis.
The deﬁnition of MV weaning in the NHI database for long-term
users differs from that in the present study (left ICU without us-
ing MV). For quality control of the existing and new MV users, no
matter how long MV was used, whether 1e21, 22e63, 94 or 124
days, all patients were considered to haveweaned successfully after
5 days. It is hoped that the future researchers may increase the
target size and investigate the weaning rate of >5 days to match the
criteria of the NHI policy and system. Lastly, for patients using
mechanical ventilation with iNO, female patient mortality was 1.56
times higher than male patient mortality (Table 3). Further studies
are required to clarify the outstanding questions in this study.
In summary, CMI, MV weaning rate, hospitalization cost, and
antibiotics costs for the 20e44 years and 45e64 years age groups
were higher than for the 65e74 years and  75 years age groups.
However, the ICU mortality rate, ICU readmission rate, and the
number of days using MV for the two younger age groups were
lower than for the two older age groups. This suggested that the
medical resource utilization and outcomes of the patients using
iNO MV varied among different age groups. Unfortunately, this
study did not perform biochemical tests to measure improvement
of oxygenation in the patients. The timing for clinicians to apply
iNO in patients to improve medical treatment remains to be
established.
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